Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
OpenAI Rejects Apple Trade Secret Theft Claims 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Add as a preferred source on Google
SYDNEY, Australia, March 21, 2018 -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or the “Company”) has announced the initiation of patient dosing in the new cohort of the TACTI-mel (Two ACTive Immunotherapies in melanoma) Phase 1 clinical trial. This clinical study is evaluating the combination of Immutep’s lead immunotherapy product candidate eftilagimod alpha (“efti” or “IMP321”) with pembrolizumab (KEYTRUDA®) in unresectable or metastatic melanoma patients in Australia.
The additional cohort consists of six patients that will receive 30 mg of efti in combination with pembrolizumab starting at cycle one of pembrolizumab. Patients will be treated for up to 12 months. Yesterday the first patient in this cohort received their first dose of the two drugs. Safety assessment is the main objective of this study.
“This additional cohort of the ongoing TACTI-mel clinicial trial is very important to the clinical development of efti, especially in the light of our new collaboration study announced on 12th of March 2018, as we are now dosing efti at cycle one in combination with KEYTRUDA® with the highest dose and for a 12-month duration,” said Dr. Frédéric Triebel, Immutep’s Chief Scientific Officer and Chief Medical Officer. “We look forward to presenting additional data from the TACTI-mel study during the middle of this calendar year as we hope it will further support our hypothesis that combining an antigen-presenting cell activator (efti) with a checkpoint inhibitor (KEYTRUDA®) results in a therapeutic synergy and a potential benefit over checkpoint inhibitor monotherapy.”
About Immutep
Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the U.S.
For further information please visit www.immutep.com or contact:
U.S. Investors:
Jay Campbell, Vice President of Business Development and Investor Relations, Immutep Limited
+1 (917) 860-9404; [email protected]
Australian Investors/Media:
Matthew Gregorowski, Citadel-MAGNUS
+61 2 8234 0105; [email protected]
